Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
AI-enabled technology platform delivers integrated pharmacovigilance solutions with measurable efficiency gains and enhanced compliance
The company secured new accounts, including ACCESS-PVI trial sites, and aims to strengthen global commercialization efforts
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Acquisition enhances integrated pharmacovigilance platform, combining AI, automation, and services to improve compliance, efficiency, and end-to-end clinical safety operations
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
